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Conclusion: The use of gated treatment in left breast 
tangential radiotherapy can result in high quantity of 
unrequested CT scans and plans for patients not needing to 
be addressed to this kind of delivery method. Our decision 
tool is able to evaluate patients that will benefit from using 
gating technology without the need to acquire a double CT 
scan and producing a double treatment plan, so making the 
whole workflow easier and faster. 
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Purpose or Objective: The conventional radiotherapy 
technique for breast cancer with locoregional lymph nodes 
consists of half beam tangential fields for the breast, 
junctioning a 3-field AP-PA half beam block for the 
supraclavicular nodes. The AP-PA fields treat a considerable 
volume of healthy tissue to high doses, and the lack of slip 
zone makes it unsuitable for deep inspiration breathhold 
where some variation of breathhold is expected. Full 
volumetric modulated arc would lead to an unwanted low-
dose spread. We therefore investigated the improvements of 
a novel hybrid RapidArc (hRA) technique which is now 
standard in our hospital. 
 
Material and Methods: Previously contoured CT scans from 
10 patients with breast tumors including lococregional lymph 
nodes were used for planning (Eclipse, Varian Medical 
Systems). Prescription was 16 fractions of 2.67 Gy. Clinically 
treated hRA plans consisted of 2 tangential open fields with a 
2 cm cranial slip zone delivering 85% of breast dose and 3 
partial RapidArc arcs of each 80°, delivering the remaining 
dose to the breast and slipzone and full dose to the cranial 
lymph nodes. A range of organs at risk (OAR) constraints 
(from high to low dose) were set on heart, contralateral (CL) 
breast, ipsilateral (IL) and CL lung, esophagus, thyroid and 
ring structures. PTV and OAR dosimetry of hRA plans were 
compared with our old conventional technique hybrid (h)-
IMRT). hIMRT plans consisted of 3 APPA half fields, delivering 
full dose to the cranial lymph nodes, 2 tangential open half 
fields delivering 85% of breast dose and 2 tangential IMRT 
fields delivering the remaining dose to the breast and 
junction. Plans were normalized to deliver similar mean 
dose. PTV and OAR metrics were compared. 
 
Results: Compared to hIMRT, hRA provided better PTV 
coverage and OAR sparing (see Table). V107% of PTV reduced 
from 4.9% to 1.3%. Both the volumes outside the PTV 
receiving 20Gy and 40Gy were reduced significantly by hRA 
(from 2014 to 1440cm3 and from 789 to 312 cm3). hRA spared 
better the esophagus and thyroid gland. Mean lung dose and 
IL lung receiving 20Gy reduced significantly, at the expense 
of a non-significant 5% increase of V5Gy to the IL lung. 
 
 
 
Conclusion: The novel hRA technique had dosimetric 
advantages for almost all investigated OAR. hRA spared 
significantly the healthy tissue around the supraclavicular 
lymph nodes. The 2cm slip zone in the hRA plan, which is not 
possible to create when using junctioning half beams, makes 
this technique also suitable for breathhold treatment. 
 
Poster Viewing: 2: Clinical: Health economics, urology and 
brain  
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Purpose or Objective: Radiotherapy centres have the 
complex task to simultaneously improve patient outcomes 
(survival and toxicity), safety, service (such as shared 
decision making) and efficiency. To address this multi headed 
challenge, centres are forced to innovate. The objective of 
our study is to investigate how well Dutch Radiotherapy 
centres have implemented innovation within the care 
environment. Our two research questions are: 1. What is the 
annual number of treatment -, technological - and 
organisational innovations? And 2. Are there differences 
between the centres?  
 
Material and Methods: A descriptive cross-sectional study 
was conducted. Two investigators started with semi 
structured interviews in participating centres, generally with 
the head of physics and the head of the department. 
Innovations in the annual policy plans from 2011- 2013 (3 
years) were classified into 3 distinct categories based on 
literature: new or significantly improved 1) treatment, 2) 
technology, or 3) organisational processes, implemented in 
clinical routine. Incremental improvements to existing 
treatments, technologies, or organisational processes were 
not included in the results below. Centres without annual 
policy plans were asked to create their own inventory, or to 
tick listed innovations from other centres. Finally, all 
participating centres received the listed innovations from 
